Molecular analysis of acid ceramidase deficiency in patients with Farber disease
✍ Scribed by Julia Bär; Thomas Linke; Klaus Ferlinz; Ulrich Neumann; Edward H. Schuchman; Konrad Sandhoff
- Book ID
- 102262170
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 319 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1059-7794
- DOI
- 10.1002/humu.5
No coin nor oath required. For personal study only.
✦ Synopsis
Farber disease is a rare, autosomal recessively inherited sphingolipid storage disorder due to the deficient activity of lysosomal acid ceramidase, leading to the accumulation of ceramide in cells and tissues. Here we report the identification of six novel mutations in the acid ceramidase gene causing Farber disease: three point mutations resulting in single amino acid substitutions, one intronic splice site mutation resulting in exon skipping, and two point mutations also leading to occasional or complete exon skipping. Of interest, these latter two mutations occurred in adjacent nucleotides and led to abnormal splicing of the same exon. Expression of the mutated acid ceramidase cDNAs in COS-1 cells and subsequent determination of acid ceramidase residual enzyme activity demonstrated that each of these mutations was the direct cause of the acid ceramidase deficiency in the respective patients. In contrast, two known polymorphisms had no effect on acid ceramidase activity. Metabolic labeling studies in fibroblasts of four patients showed that even though acid ceramidase precursor protein was synthesized in these individuals, rapid proteolysis of the mutated, mature acid ceramidase occurred within the lysosome. Hum Mutat 17:199-209, 2001.
📜 SIMILAR VOLUMES
The most common mutation in muscle carnitine palmitoyltransferase II (CPT II) deficiency is a missense mutation that replaces a leucine for a serine residue at amino acid position 113 of the CPT II protein (S113L). We performed molecular analysis in a group of 14 Spanish patients with CPT II deficie